Pepkon is a biotechnology company that develops first-in-class peptides for the treatment of incurable or poor prognosis cancers.

PepKon is developing small peptides mimicking the C-terminal domain of Thrombospondin-1. They treat several leukemias and solid cancers, including pediatric and orphan types. PepKon objective is to rapidly reach